Merck KGaA suffers setback on cancer drug

July 5, 2012

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

The trials found that in combination with standard chemotherapy, did not extend "the length of time that patients live without their disease getting worse," Merck KGaA said in a statement.

"We are disappointed that the ... trial did not show a benefit for patients with advanced gastric cancer when Erbitux was added to standard chemotherapy," said Florian Lordick, in charge of the clinical trials.

"Understandably, these results are disappointing for patients with advanced , and as a company we will continue to invest in oncology research and development to find new treatments for these diseases," said Merck's head of drug development, Annalisa Jenkins.

The results would not alter the proven utility of Erbitux in its already approved indications for metastatic and , Merck KGaA said.

The news hit Merck KGaA shares which were showing a loss of 0.38 percent at 79.65 euros in mid-morning trade on the Frankfurt stock exchange in a generally firmer market.

Explore further: High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy

Related Stories

Recommended for you

Study: Enhancing cancer response to radiation

December 2, 2016

OHSU researcher Sudarshan Anand, Ph.D., has a contemporary analogy to describe microRNA: "I sometimes compare MicroRNA to tweets—they're short, transient and constantly changing."

Rare childhood disease linked to major cancer gene

December 1, 2016

A team of researchers led by a University of Rhode Island scientist has discovered an important molecular link between a rare childhood genetic disease, Fanconi anemia, and a major cancer gene called PTEN. The discovery improves ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.